Network

A network of European centres collects European pharmacokinetic data in pregnant women. The initiator of this European network is Prof. Dr. David Burger at the Radboud University Nijmegen Medical Centre, the Netherlands. Wendy van der Wekken is the coordinator of the PANNA study from October 2024. Dr. Angela Colbers was the coordinator of the PANNA study till October 2024.

Why setting up a European Network?

In the US, a network performing PK studies (amongst other research) in pregnant women is in place: IMPAACT (formerly PACTG). The US population is a different patient population compared to the European population.

The EMA requires data in the European population as well: “patients entering clinical trials should be reasonably representative of the population that will be later treated by the drug”. In Europe, the demographics of HIV-infected pregnant women (Caucasian females and females born in Sub-Saharan Africa) are different from the US population.
Over

study centres

Participate as a new study centre

To apply for participation in the study you can fill in the contact details of your centre in the application form. After your application you will be contacted for screening and you will receive further information on how to start up the PANNA study in your centre.

Requirements

  • capability of doing 12h or 24h PK recordings
  • access to a research unit/clinical ward for in-house PK sampling
  • research nurse & lab facilities (handling, storage)
  • large clinical site (>40 deliveries/year)
  • having a multidisciplinary team (ID specialist, gynaecologists/obstetricians, paediatricians)

Application form

Please fill in the apllication form to receive further information to participate as a new study centre.

Study centres

As a physician you can include patients by referral to a study centre near you. Choose your country and find the nearest centre for more information.

It is also possible to participate as a study centre in the PANNA study. Are you interested in applying? Please read the requirements and apply.

Click on your country

IRCSS

Roma
Dr. A. Antinori

Closed for inclusion.

University of Padua

Padua
Carlo Giaquinto

Not open for inclusion.

University of Torino

Torino
Giovanni di Perri

Not open for inclusion.

CHARITÉ Berlin

Berlin
Dr. med. Katharina Weizäcker / Dr. med. Jan-Peter Siedentopf / Dr. med. Thorsten Braun

Open for inclusion.

Johann Wolfgang Goethe-Universität

Frankfurt am Main
Dr.med. Annette Haberl

Open for inclusion

University München

München
Dr.med. Kost / Dr.med. Fabian Weiss

Open for inclusion.

University of Bonn

Bonn
Prof. Dr. Jürgen Rockstroh / Dr. Jan-Christian Wasmuth / Dr. Kathrin van Bremen

Open for inclusion.

University of Cologne

Köln
Dr. Med. Jakob Malin

Open for inclusion.

Hospital Universitari Germans Trias I Pujol

Barcelona
José Molto (investigator)/Cristina Miranda (study coordinator)

Open for inclusion.

Hospital Universitario Virgen de las Nieves Granada; Médico Adjunto del Servicio de Medicina Interna

Granada
dr Carmen Hidalgo Tenori

Open for inclusion.

AMC

Amsterdam
Jeannine Nellen

Not open for inclusion.

Erasmus Medical Centre Rotterdam

Rotterdam
Dr. C. Rokx, Dr. B. Rijnders

Open for inclusion.

Radboud university medical center

Nijmegen
Prof. Dr. Reinout van Crevel

Open for inclusion.

St Elisabeth Ziekenhuis

Tilburg
Dr. M.E.E. van Kasteren

Satellite site in The Netherlands, open for inclusion.

Brighton and Sussex University Hospitals NHS Trust

Brighton
Y. Gilleece, MD

Satellite site for UK, open for inclusion.

C&W Hospital

London
David Hawkins

Open for inclusion.

St Mary’s Hospital

London
Dr. G. Taylor

Open for inclusion.

Mater Hospital and UCD, Dublin

Dublin
dr John Lambert

Open for inclusion.

St James’s Hospital Dublin

Dublin
Dr Fiona Lyons

Open for inclusion.

Saint-Pierre University Hospital; Department of Infectious Diseases

Brussels
dr Konopnicki

Open for inclusion.

Curaçao Medical Center

Willemstad
dr van de Wetering

Open for inclusion.

Sponsors

The PANNA study is powered by: